Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk.

Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Abstract Text:

Shelley S Tworoger,Kathleen M Fairfield,Graham A Colditz,Bernard A Rosner,Susan E Hankinson,

Although oral contraceptives are protective for ovarian cancer, it is unclear how long this protection persists. The authors prospectively assessed this question as well as associations of other, less studied contraceptive methods (tubal ligation, rhythm method, diaphragm, condoms, intrauterine device, foam, spousal vasectomy) and infertility with ovarian cancer risk among 107,900 participants in the US Nurses' Health Study. During 28 years of follow-up (1976-2004), 612 cases of invasive epithelial ovarian cancer were confirmed. Duration of oral contraceptive use was inversely associated with risk (p-trend = 0.02), but no clear trend was observed for years since last use. However, for women using oral contraceptives for >5 years, the rate ratio for ovarian cancer for 20 years since last use (rate ratio (RR) = 0.92, 95% CI: 0.61, 1.39). Tubal ligation (RR = 0.66, 95% CI: 0.50, 0.87) was associated with decreased ovarian cancer risk, whereas intrauterine device use (RR = 1.76, 95% CI: 1.08, 2.85) and infertility (RR = 1.36, 95% CI: 1.07, 1.75) were associated with an increased risk. Results suggest that the beneficial effect of oral contraceptives on ovarian cancer risk attenuates after 20 years since last use. Furthermore, tubal ligation, intrauterine device use, and infertility were associated with ovarian cancer risk.

Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Publishing Authors By Initials

SS Tworoger,KM Fairfield,GA Colditz,BA Rosner,SE Hankinson,

For similar geographic locations: americas: north america: united states research abstracts see: geographic locations: americas: north america: united states research

PUBMED ID PMID:

MEDLINE DATE:

Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: American journal of epidemiology

VOLUME: 166

Page Numbers: 894-901

Journal Abbreviation: Am. J. Epidemiol.

ISSN: 0002-9262

DAY: 26

MONTH: 07

YEAR: 2007

Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7910653

Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Keywords Mesh Terms:

KEYWORDS: United States

MESH TERMS: epidemiology

Chemical & Substance for Abstract: Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Information

Substance Name: Contraceptives, Oral, Hormonal

Registry Number: 0

Grant and Affiliation Information for Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk.

AFFILIATION: Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. nhsst@channing.harvard.edu

Country: United States

AGENCY: United States NCI

GRANT: P50 CA105009

ACRONYM: CA

MEDLINETA: Am J Epidemiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk Related Publications

• A novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of cytochrome P4502S1 by both dioxin and hypoxia.
• A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer.
• A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.
• A prospective study of postmenopausal hormone use and ovarian cancer risk.
• Aspirin, NSAID, and Acetaminophen Use and the Risk of Endometrial Cancer.
• Association of activity and chronic disease risk factors: utility and limitations of objectively measured physical activity data.
• Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk.
• Birthweight and body size throughout life in relation to sex hormones and prolactin concentrations in premenopausal women.
• Body shape throughout life and correlations with IGFs and GH.
• Breastfeeding and risk of ovarian cancer in two prospective cohorts.
• Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer.
• Circulating colony stimulating factor-1 and breast cancer risk.
• Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women.
• Circulating levels of sex steroids and prolactin in premenopausal women and risk of breast cancer.
• Dietary patterns, the Alternate Healthy Eating Index and plasma sex hormone concentrations in postmenopausal women.
• Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women.
• Identification of novel dioxin-responsive genes by representational difference analysis.
• Identifying target genes of the aryl hydrocarbon receptor nuclear translocator (Arnt) using DNA microarray analysis.
• Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts.
• Menopausal and reproductive factors and risk of age-related macular degeneration.
• Physical activity and inactivity in relation to sex hormone, prolactin, and insulin-like growth factor concentrations in premenopausal women - exercise and premenopausal hormones.
• Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer.
• Plasma adiponectin concentrations and risk of incident breast cancer.
• Plasma androgen concentrations and risk of incident ovarian cancer.
• Prolactin and breast cancer risk.
• Relationship of plasma adiponectin with sex hormone and insulin-like growth factor levels.
• Reproducibility of proteomic profiles over 3 years in postmenopausal women not taking postmenopausal hormones.
• The role of the aryl hydrocarbon receptor nuclear translocator protein in aryl hydrocarbon receptor action.
• Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis.
• Why does ARNT2 behave differently from ARNT?